CINC Key Statistics, Chart & Performance
The current stock price of CINC is 29.06 USD. In the past month the price increased by 1.15%. In the past year, price increased by 2%.
CINC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CINC. When comparing the yearly performance of all stocks, CINC is one of the better performing stocks in the market, outperforming 81.02% of all stocks.
CINC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CINC. While CINC has a great health rating, there are worries on its profitability.
CINC Financial Highlights
Over the last trailing twelve months CINC reported a non-GAAP Earnings per Share(EPS) of -17.28. The EPS decreased by -125.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CINC Forecast & Estimates
12 analysts have analysed CINC and the average price target is 39.78 USD. This implies a price increase of 36.89% is expected in the next year compared to the current price of 29.06.
CINC Ownership
CINC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.13 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.1 | 293.697B | ||
| PFE | PFIZER INC | 8.91 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.85 | 117.3B | ||
| ZTS | ZOETIS INC | 18.47 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.43 | 25.214B | ||
| VTRS | VIATRIS INC | 5.65 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.1 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.58 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CINC
Company Profile
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
Company Info
CINCOR PHARMA INC
230 Third Ave., 6Th Floor
Waltham MASSACHUSETTS US
Employees: 19
Phone: 18445311834.0
CINCOR PHARMA INC / CINC FAQ
Can you describe the business of CINCOR PHARMA INC?
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
What is the stock price of CINCOR PHARMA INC today?
The current stock price of CINC is 29.06 USD. The price decreased by -0.48% in the last trading session.
What is the dividend status of CINCOR PHARMA INC?
CINC does not pay a dividend.
What is the ChartMill rating of CINCOR PHARMA INC stock?
CINC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CINC stock listed?
CINC stock is listed on the Nasdaq exchange.
What is the market capitalization of CINC stock?
CINCOR PHARMA INC (CINC) has a market capitalization of 1.27B USD. This makes CINC a Small Cap stock.